|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Headache: The Journal of Head and Face PainVolume 45 Issue 5, Pages 546 - 552 Published Online: 9 Jun 2005 © 2010 American Headache Society Published on behalf of the American Headache Society
Abstract | References | Full Text: HTML, PDF (Size: 84K) | Related Articles | Citation Tracking  Research Submission Cortical Inhibition Is Reduced in Chronic and Episodic Migraine and Demonstrates a Spectrum of Illness From the Swedish Headache Center, Seattle, WA (Dr. Aurora and Barrodale); University of Hawaii at Manoa, Department of Psychology, Honolulu, HI (Dr. Chronicle); and Canisius Wilhelmina, Department of Neurology, Nijmegen, Netherlands Antilles, The Netherlands (Dr. Mulleners). Copyright 2005 by the American Headache Society KEYWORDS chronic migraine • transcranial magnetic stimulation • cortical excitability (Headache 2005;45:546-552) ABSTRACTBackground.—The pathophysiological relationship between episodic migraine and chronic migraine is not fully understood. We aimed to examine transcranial magnetic stimulation (TMS) indices of cortical excitability in patients with episodic migraine (EM) and probable chronic migraine (PCM), and matched controls. Methods.—Cortical excitability was assessed at baseline with two well-established methods: phosphene thresholds (PT) and magnetic suppression of perceptual accuracy (MSPA) profiles. Five EM patients, five PCM patients, and five normal controls participated in the main study. In addition, two patients were reassessed after 30 days of treatment with topiramate. Results.—Both PT and MPSA measures were consistent in indicating a continuum of excitability across the three groups: PCM patients had the highest excitability, followed by EM, then controls. In the two treated patients MPSA profiles appeared to normalize at a 100 mg dosage. Conclusions.—Patients with PCM appear to be characterized by very high cortical excitability. This may contribute to their greatly increased attack frequency. TMS-based methods will be important for future research examining the evolution of chronic migraine from episodic migraine over time. Accepted for publication January 4, 2005. | 
|
